sotagliflozin
Sponsor Lexicon Pharmaceuticals, INC. · listed as LXRX
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
Next catalyst
Event typeREADOUT
Expected date2026-07-31
As disclosedJul 2026
Date precisionmonth
Confidencemedium
Trial & sponsor
Trial (NCT)NCT06481891
PhasePHASE3
StatusRECRUITING
Lead sponsorLexicon Pharmaceuticals
Listed asLXRX
Condition(s)Obstructive Cardiomyopathy, Hypertrophic; Non-obstructive Hypertrophic Cardiomyopathy
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More LXRX catalysts